Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 277 results
Filters: Author is Dubé, Michael P  [Clear All Filters]
Found 277 results.

Adult

Blodget E, Shen C, Aldrovandi G, et al. "Relationship between microbial translocation and endothelial function in HIV infected patients." PLoS ONE. 2012;7(8):e42624.
Dubé MP, Komarow L, Fichtenbaum CJ, et al. "Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation." Clin. Infect. Dis.. 2015;61(5):840-9.
Brown TT, Chen Y, Currier JS, et al. "Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals." J. Acquir. Immune Defic. Syndr.. 2013;63(3):323-30.
Kelesidis T, Jackson N, McComsey GA, et al. "Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection." AIDS. 2016;30(17):2625-2633.
Kelesidis T, Tran TTien T, Stein JH, et al. "Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." Clin. Infect. Dis.. 2015;61(4):651-60.
Stein JH, Brown TT, Ribaudo HJ, et al. "Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection." AIDS. 2013;27(6):929-37.
Grant PM, Kitch D, McComsey GA, et al. "Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation." Clin. Infect. Dis.. 2013;57(10):1483-8.
Ranade K, Geese WJ, Noor M, et al. "Genetic analysis implicates resistin in HIV lipodystrophy." AIDS. 2008;22(13):1561-8.
Hulgan T, Stein JH, Cotter BR, et al. "Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation." AIDS Res. Hum. Retroviruses. 2013;29(10):1293-9.
Mulligan K, Parker RA, Komarow L, et al. "Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial." J. Acquir. Immune Defic. Syndr.. 2006;41(5):590-7.
Brown TT, Moser C, Currier JS, et al. "Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir." J. Infect. Dis.. 2015;212(8):1241-9.
Dubé MP, Parker RA, Mulligan K, et al. "Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384." Clin. Infect. Dis.. 2007;45(1):120-6.
Dubé MP, Komarow L, Mulligan K, et al. "Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384." J. Acquir. Immune Defic. Syndr.. 2007;45(5):508-14.
Stein JH, Ribaudo HJ, Hodis HN, et al. "A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness." AIDS. 2015;29(14):1775-83.
Dubé MP, Wu JW, Aberg JA, et al. "Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148." Antivir. Ther. (Lond.). 2006;11(8):1081-9.
Torriani FJ, Komarow L, Parker RA, et al. "Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s." J. Am. Coll. Cardiol.. 2008;52(7):569-76.

Pages